Indeed, studies showed that a subset of FOXA1 genome binding sites can be reprogrammed either by steroid hormone-activated GR and ER in breast cancer cells (36) or by neuroendocrine prostate cancer driver TFs ASCL1 and NKX2-1 (37). This evidence concerns the gene FOXA1 and breast carcinoma.